Skip to content

OWC Pharmaceutical Research Corp.: 10-Q filed 2016-10-24

What OWC Pharmaceutical Research Corp. reported in its quarterly report filed 2016-10-24 (fiscal Q2 2016): 16 published measures, 42 facts as tagged in accession 0001295345-16-000721.

This filing

Form
10-Q (quarterly report)
Filed
2016-10-24
Fiscal period
fiscal Q2 2016
Accession
0001295345-16-000721 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All OWC Pharmaceutical Research Corp. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-06-30238,951USD
At 2015-12-31430,448USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-06-30350,992USD
At 2015-12-31107,626USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-06-30-149,541USD
At 2015-12-31322,822USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-01-01 to 2016-06-30-488,118USD182
2015-01-01 to 2015-06-30-1,014,030USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2016-01-01 to 2016-06-30-271,949USD182
2015-01-01 to 2015-06-30-751,105USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2016-04-01 to 2016-06-300USD91
2016-01-01 to 2016-06-300USD182
2015-04-01 to 2015-06-300USD91
2015-01-01 to 2015-06-300USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2016-01-01 to 2016-06-3071,250USD182
2015-01-01 to 2015-06-3090,000USD181

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-40,562USD91
2016-01-01 to 2016-06-30-41,560USD182
2015-04-01 to 2015-06-300USD91
2015-01-01 to 2015-06-300USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-04-01 to 2016-06-3034,776USD91
2016-01-01 to 2016-06-3071,819USD182
2015-04-01 to 2015-06-3076,612USD91
2015-01-01 to 2015-06-30189,940USD181

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2016-06-308,541,599USD
At 2015-12-318,533,525USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-177,682USD91
2016-01-01 to 2016-06-30-480,437USD182
2015-04-01 to 2015-06-30-610,077USD91
2015-01-01 to 2015-06-30-1,019,638USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-04-01 to 2016-06-3084,467USD91
2016-01-01 to 2016-06-30306,023USD182
2015-04-01 to 2015-06-30532,815USD91
2015-01-01 to 2015-06-30824,090USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2016-01-01 to 2016-06-304,825USD182
2015-01-01 to 2015-06-304,524USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2016-01-01 to 2016-06-300USD182
2015-01-01 to 2015-06-3090,000USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-06-304,098USD182
2015-01-01 to 2015-06-300USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-06-303,589USD182
2015-01-01 to 2015-06-3035,763USD181

Inspect the source

Entity
OWC Pharmaceutical Research Corp. / CIK 0001431934
Captured
SEC response SHA-256
5a62036473d89e622be102a608ba10aaa02db1a8778e5f34f9de1894da63b491

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001431934.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))